论文部分内容阅读
西安一枝刘制药有限公司的科研人员经过多年的努力,最近从中国红豆杉树皮中分离的内真菌培养生产紫杉醇取得突破,经国际联机文献检索,这项成果处于国际领先水平。专家们认为,这一成果为保护医药资源,发展紫杉醇规模生产具有重大意义。 紫杉醇以其抗癌机理独特和疗效显著而风靡全球,是国际市场上的抢手产品。目前国内外普遍采取从红豆杉树中直接提取紫杉醇的办法,不仅产量极少,而且造成了红豆杉资源濒危。西安一枝刘制药有
The researchers of Xi’an Yizhi Liu Pharmaceutical Co., Ltd., after years of hard work, have recently made breakthroughs in the production of taxol from the culture of endophytes isolated from the bark of Chinese yew. After the international online literature search, this achievement is at the leading level in the world. Experts believe that this achievement is of great significance for the protection of medical resources and the development of scale production of paclitaxel. Paclitaxel is a popular product in the international market due to its unique anti-cancer mechanism and remarkable clinical efficacy. At present, the method of directly extracting paclitaxel from the yew tree is widely adopted at home and abroad, and not only the yield is very small, but also the yew resources are endangered. Xi’an Liuzhi Pharmaceutical has